The Key to Hope Lies in Research
The Key to Hope Lies in Research When Joanne Downing first noticed a lump in her neck while playing golf one sunny Florida day in 2001, her first inclination was to dismiss it. However, her friend and golf partner —…
News
ASH 2024: Inequitable Patterns in Fertility Counseling Reported by Patients with NHL
ASH 2024: Inequitable Patterns in Fertility Counseling Reported by Patients with NHL Late effects from non-Hodgkin lymphoma (NHL) treatment can lead to decreased fertility, which may be of particular concern for adolescents and young adults. Utilization of fertility counseling is…
ASH 2024: Real-World Clinical Outcomes With Novel Therapies in Relapsed/Refractory MCL Vary Based on Race and Ethnicity
ASH 2024: Real-World Clinical Outcomes With Novel Therapies in Relapsed/Refractory MCL Vary Based on Race and Ethnicity The treatment for relapsed/refractory mantle cell lymphoma (MCL) has been revolutionized by the emergence of novel therapies such as Bruton’s tyrosine kinase inhibitors…
ASH 2024: First-Line Treatment Choice Impacts Risk for Other Malignancies in CLL and SLL
ASH 2024: First-Line Treatment Choice Impacts Risk for Other Malignancies in CLL and SLL Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have previously been shown to be at increased risk for developing other malignancies relatively to…
ASH 2024: Interim Results from the AMPLIFY Study Show Durable Responses with Acalabrutinib Plus Venetoclax in Treatment-Naïve CLL
ASH 2024: Interim Results from the AMPLIFY Study Show Durable Responses with Acalabrutinib Plus Venetoclax in Treatment-Naïve CLL Use of fixed-duration Bruton tyrosine kinase inhibitor (BTKi) therapy in treatment-naïve chronic lymphocytic leukemia (CLL) is complicated by the limited efficacy and…
ASH 2024: High Rates of Disease Control Without Radiotherapy Observed Following Incorporation of Nivolumab in Early Stage cHL
ASH 2024: High Rates of Disease Control Without Radiotherapy Observed Following Incorporation of Nivolumab in Early Stage cHL As treatment options for classic Hodgkin lymphoma (cHL) have improved, minimizing late effects while maximizing treatment efficacy has become a critical goal…
ASH 2024: Phase III Study of Glofitamab Plus Pola-R-CHP Ongoing in Patients with Previously Untreated CD20-Positive LBCL
ASH 2024: Phase III Study of Glofitamab Plus Pola-R-CHP Ongoing in Patients with Previously Untreated CD20-Positive LBCL Combination therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, known as R-CHOP, is a standard first-line treatment option for patients with diffuse large…
ASH 2024: High Response Rates Observed with Loncastuximab Tesirine Plus Rituximab in High-Risk Patients with Relapsed/Refractory FL
ASH 2024: High Response Rates Observed with Loncastuximab Tesirine Plus Rituximab in High-Risk Patients with Relapsed/Refractory FL Loncastuximab tesirine (loncastuximab) is an antibody-drug conjugate used to treat certain types of B-cell lymphomas. The phase I study of loncastuximab showed promise…
ASH 2024: Poor Outcomes Observed Following Disease Progression After CD19-Directed CAR T-Cell Therapy
ASH 2024: Poor Outcomes Observed Following Disease Progression After CD19-Directed CAR T-Cell Therapy Chimeric antigen receptor (CAR) T-cell therapies have become a standard treatment option for many patients with relapsed or refractory mantle cell lymphoma (MCL). While these therapies are…
Cancer Leadership Council Statement on Medicaid and Support for Cancer Patients
Cancer Leadership Council Statement on Medicaid and Support for Cancer Patients A Congressional budget resolution targeting potential reductions to federal Medicaid spending is being considered by the House of Representatives this week. Medicaid is the primary program providing comprehensive health…